Document is current
Any future updates will be listed below
-
Authors
Kregting, Lindy https://orcid.org/0000-0002-8262-0080
van den Oever, Daan
Pennings, Lian
Pijnappel, Ruud
van Ravesteyn, Nicolien
Verschuur, Ellen
van Oirsouw, Marja
Dunning, Loes
‘t Mannetje, Hans
van Engen, Ruben
Bluekens, Adriana
Smid-Geirnaerdt, Maartje
van Landsveld-Verhoeven, Cary
Houssami, Nehmat
Sechopoulos, Ioannis
Broeders, Mireille
-
Funding
Funding for this research was provided by:
ZonMW (05550402130002)
KWF Kankerbestrijding (2021–13710)
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 19 August 2024
Accepted: 11 November 2024
First Online: 9 January 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Mireille Broeders.
: The authors of this manuscript declare relationships with the following companies: Mireille Broeders: Research/grant support: Screenpoint Medical, Sectra Benelux, Hologic, Volpara Solutions, Lunit Inc., iCAD. Speaker: Hologic, Siemens Healthcare. Ioannis Sechopoulos: Research/grants support: Siemens Healthcare, Canon Medical, Screenpoint Medical, Sectra Benelux, Hologic, Volpara Solutions, Lunit Inc, iCAD, E-COM. Speaker: Siemens Healthcare, Canon Medical. Advisory Board: Koning Corp. Nicolien van Ravesteyn: fees for consulting from Wickenstones (paid to institution). The remaining authors declare no conflicts of interest.
: One of the authors (Mireille Broeders) has significant statistical expertise.
: Written informed consent was obtained from all subjects in the intervention arm in this study. Written informed consent was not required for the control arm because, in the Netherlands, informed consent is implied for the use of pseudonymised or aggregated cancer screening data when one takes up the offer of screening unless the individual specifically opts out. Individuals who withdrew consent, will not be included in the control arm.
: The Minister of Health, Welfare and Sport has granted ethical approval and a license to conduct this trial from 1 May 2023 to 1 June 2028 (Registration number: 3574709-1044141-PG). This is considered equivalent to approval by an institutional review board.
:
